Syringofibroadenoma

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Syringofibroadenoma
Syringofibroadenoma
Synonyms
Pronounce	N/A
Specialty	N/A
Symptoms	Skin lesion, papule, nodule
Complications
Onset
Duration
Types
Causes	Unknown
Risks
Diagnosis	Skin biopsy, histopathology
Differential diagnosis	Basal cell carcinoma, squamous cell carcinoma, trichoepithelioma
Prevention
Treatment	Surgical excision
Medication
Prognosis	Generally good
Frequency	Rare
Deaths	N/A

Syringofibroadenoma is a rare skin condition characterized by the development of benign tumors in the sweat glands. First described by Mascaro in 1963, syringofibroadenoma has since been recognized as a distinct entity in dermatological and pathological literature. The condition can present as a solitary nodule or multiple nodules, primarily affecting the extremities, although occurrences on other parts of the body have been reported.

Etiology and Pathogenesis

The exact cause of syringofibroadenoma remains unclear. It is believed to arise from eccrine sweat glands, which are a type of sweat gland involved in thermoregulation. Some theories suggest that syringofibroadenoma may develop as a reactive process to chronic inflammation or injury, while others propose a genetic predisposition. There is also evidence to suggest that it may occur in association with other skin conditions, such as dermatitis, psoriasis, and various forms of epidermal nevus.

Clinical Presentation

Patients with syringofibroadenoma typically present with solitary or multiple flesh-colored, verrucous, or nodular lesions. These lesions are often asymptomatic but can occasionally be painful or pruritic. The most common sites of involvement are the palms and soles, reflecting the high density of eccrine sweat glands in these areas. However, lesions can also appear on the limbs, trunk, and face.

Diagnosis

The diagnosis of syringofibroadenoma is primarily based on histopathological examination. Characteristic findings include anastomosing cords and strands of epithelial cells embedded in a fibrovascular stroma, extending from the epidermis into the dermis. Ductal structures, consistent with eccrine differentiation, are often observed within the tumor. Immunohistochemistry may be used to further support the diagnosis, with tumor cells typically expressing markers of eccrine differentiation.

Treatment

Treatment options for syringofibroadenoma vary depending on the number, size, and location of lesions, as well as the presence of symptoms or associated conditions. Surgical excision is the most definitive treatment for solitary lesions. For multiple lesions, other treatment modalities may be considered, including cryotherapy, electrosurgery, and laser therapy. In cases associated with underlying skin conditions, management of the primary condition is also important.

Prognosis

The prognosis for patients with syringofibroadenoma is generally good, as the tumors are benign and do not metastasize. However, recurrence after treatment is possible, especially if the lesions are not completely excised. Regular follow-up is recommended to monitor for recurrence or the development of new lesions.